Sound Pharma reports Phase 3 hearing gains with SPI-1005, targeting sudden hearing loss
Sound Pharmaceuticals has presented a new Phase 3 analysis showing statistically significant low-to-mid-frequency hearing improvements with SPI-1005 in Ménière's disease. The company believes the findings support development for sudden sensorineural hearing loss, although that separate indication has not been established in a dedicated pivotal trial.